Commentary
This review by A. Majumdar (Australian National Liver Transplant Unit, Royal Prince Alfred Hospital, Sydney, and University of Sydney, Australia) and E. Tsochatzis (UCL Institute for Liver and Digestive Health, Royal Free Hospital and UCL, London, and Sheila Sherlock Liver Centre, Royal Free Hospital, London, UK) outlines the current epidemiology, natural history and outcomes of NAFLD with a focus on pre- and post-liver transplant settings.
NAFLD poses several challenges in the peri-transplant setting including the management of multiple metabolic co-morbidities, post-transplant obesity and cardiovascular risk. However, post-liver transplantation outcomes in well-selected NAFLD patients appear similar to non-NAFLD indications, including in the setting of hepatocellular carcinoma.
